Top of this page
Skip navigation, go straight to the content

Partnering for brain research

  • Posted by

    At UCB, we believe partnership is essential to making science progress and improving the lives of people living with severe diseases. That is why we are collaborating with Weill Cornell Medical College in New York to prevent brain cell loss in epilepsy patients.

    Building on a collaboration established last year in the areas of metabolic disease, bone disorders and rare genetic variant analysis, the new project focuses on preventing neuronal cell loss as part of our Technology Access: Antibody Platform programme.

    Both partners – UCB and Weill Cornell – bring their unique knowhow to the project. UCB’s world-leading antibody discovery capabilities will provide tools to dissect disease mechanisms, while the knowledge and capabilities of Professor Barbara Hempstead at Weill Cornell will ensure scientific excellence with deep understanding and capabilities to study core disease mechanisms. To further the partnership between UCB and Weill Cornell, Weill Cornell receives research support from UCB.

    Specifically, together we will study the mechanisms that cause neuronal loss when seizures occur in people with epilepsy. Our scientists will use UCB’s cutting-edge technological platform and expertise to discover antibodies for the Weill Cornell lab to work with.

    If successful the project will catalyse the development of innovative targeted therapeutics that prevent neuronal cell loss and decline in brain function in patients.

    This new chapter in UCB’s alliance with Weill Cornell demonstrates our shared commitment to long-term collaboration. For us, it is also the latest in a series of link-ups dedicated to turning scientific discovery into transformative health improvements for patients.

    Tags:
    Categories:
    Share:
  • Like

Leave a Comment